Daclizumab dosing strategies in simultaneous kidney/pancreas transplant

Phase 4, randomised, open-label trial of daclizumab in kidney transplant rejection and pancreas transplant rejection (3 arms), sponsored by University of Cincinnati. Primary endpoint: Incidence of presumed acute kidney or pancreas rejection, death, and kidney or pancreas graft loss at 6 months. Started Apr 1999; status: completed.